Genentech’s Columbi meets primary endpoint in phase 3 trial for lymphoma treatment
Betsy Goodfellow | April 15, 2024 | News story | Research and Development | Columbi, Genentech, Oncology, Roche, clinical trial, lymphoma
Genentech, part of the Roche Group, has announced that its phase 3 STARGLO trial has met its primary endpoint of overall survival. The trial assessed Columvi (glofitamab-gxbm) for the treatment of patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who have had at least one prior therapy and are not candidates for autologous stem cell transplant.
The drug is a ‘CD20xCD3 T-cell engaging bispecific antibody designed to be off-the-shelf and ready for infusion, so patients can start treatment soon after diagnosis’, according to the company’s press release.
Columvi in combination with gemcitabine and oxaliplatin (GemOx) was shown to improve patients’ overall survival when compared to Rituxan (rituximab) in combination with GemOx. The combination appeared to be similar to the known safety profiles of the two individual drugs.
The full data is expected to be shared at an upcoming medical meeting as well as being submitted to the relevant health authorities.
Levi Garraway MD PhD, Genentech’s chief medical officer and head of global product development, commented: “People with this aggressive lymphoma facing relapse or progression after initial treatment have limited options – particularly those who are ineligible for stem cell transplant. Building on Columvi’s established benefits, these data demonstrate the potential of this combination regimen to improve survival outcomes in earlier lines of treatment.”
Betsy Goodfellow
Related Content
Roche secures CE Mark for automated latent tuberculosis blood test
Roche has received CE Mark approval for its Elecsys IGRA TB test, an automated blood …
Roche adds 2,176 NVIDIA Blackwell GPUs to its hybrid-cloud AI factory
Roche has expanded its global AI infrastructure with a NVIDIA AI factory, adding 2,176 high-performance …
UCB announces first-in-patient trial success for galvokimig in atopic dermatitis
UCB has reported positive early clinical trial results for galvokimig, an investigational therapy for adults …
